NSRX Nasus Pharma Ltd. Ordinary Shares

AMEX · US · Healthcare · Drug Manufacturers - General · nasuspharma.com

3.920USD+2.75%Mkt Cap: 45.92M $P/E: —3d ago

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute…

Industry Peers

Drug Manufacturers - General

Screen all

LLY

Eli Lilly and Company Common Stock

$1.02TUSDP/E 38.4

JNJ

Johnson & Johnson Common Stock

$617.01BUSDP/E 29.7

ABBV

AbbVie Inc. Common Stock

$464.43BUSDP/E 74.2

MRK

Merck & Company, Inc. Common Stock (new)

Novartis AG Common Stock

AstraZeneca PLC Ordinary Shares

Amgen Inc. - Common Stock

Gilead Sciences, Inc. - Common Stock

$179.47BUSD

NVO

Novo Nordisk A/S Common Stock

$164.79BUSDP/E 9.4

PFE

Pfizer, Inc. Common Stock

$158.45BUSDP/E 36.6

BMY

Bristol-Myers Squibb Company Common Stock

$124.91BUSDP/E 13.5

SNY

Sanofi - American Depositary Shares

$95.65BUSDP/E 21.8

GSK

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Key Statistics

Company

Market Cap45.92M USD

Enterprise Value34.19M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-5.86M USD

Revenue/Share—

Last Price3.920 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees7

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - General

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B4.17

EPS (TTM)-1.20

EPS (Forward)—

52W Range

1.98026% of range9.500

52W High9.500 USD

52W Low1.980 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-211.56%

ROA-117.03%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-4.92M USD

CapEx (TTM)14.00K USD

FCF Margin—

FCF Yield-15.21%

Net Debt-11.71M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity0.04

Current Ratio8.77

Quick Ratio8.42

Book Value/Sh0.94 USD

Cash/Share1.01 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.0 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)19.67 USD

Upside (mean)+401.7%

Target Range18.00 USD – 22.00 USD

18.00+401.7% to mean22.00

# Analysts3

Ownership

Shares Out.11.71M

Float5.46M

Insiders49.15%

Institutions18.36%

Short Interest

Short Ratio6.4d

Short % Float1.23%

Short % Out.0.69%

Shares Short80.53K

Short (prev mo.)144.51K

Technical

SMA 503.580 (+9.5%)

SMA 2004.037 (-2.9%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)18.23K

Avg Vol (10d)32.22K

Technical Indicators

RSI (14)61.3

MACD0.0309

MACD Signal-0.0008

MACD Hist.+0.0317

BB Upper3.900 USD

BB Middle3.594 USD

BB Lower3.287 USD

BB Width17.04%

ATR (14)0.3037 USD

Vol Ratio (20d)1.44x